Kairos Pharma (KAPA) Q4 2025 earnings summary

Executive summary

• Clinical-stage biopharma focused on immunotherapy and cell therapy for oncology, targeting immune suppression and drug resistance.

• Pipeline includes seven drug candidates, with lead programs in prostate and lung cancer (ENV 105) and glioblastoma (KROS 201).

• No products approved or commercialized; all revenue to date from financing activities.

• Operations are virtual, with a small team and reliance on third-party vendors and academic partnerships.

Financial highlights

• Net loss of $5.4 million for 2025, up from $2.6 million in 2024, driven by increased R&D and G&A expenses.

• Research and development expenses rose to $2.1 million in 2025 (from $0.4 million in 2024) due to clinical trial activity.

• General and administrative expenses increased to $3.4 million in 2025 (from $1.9 million in 2024), reflecting public company costs and vendor advances.

• Cash and short-term investments of $4.5 million as of December 31, 2025.

• Accumulated deficit of $14.3 million as of year-end 2025.

• No revenue from product sales; all funding from equity, PIPE, and ELOC agreements.

Outlook and guidance

• Management expects continued operating losses and negative cash flows as clinical programs advance.

• Existing cash may not fund operations for the next 12 months; additional financing will be required.

• Focus remains on progressing clinical trials for ENV 105 (prostate and lung cancer) and KROS 201 (glioblastoma).